reports
Walker & Dunlop Inc: 1 director
A director at Walker & Dunlop Inc sold 4,533 shares at 97.330USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Safe Bulkers Inc: 1 director
A director at Safe Bulkers Inc sold 40,000 shares at 5.347USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Stephane Beyazian
Telefonica : Le Brésil tire toujours l’activité
>Un T1 2024 en ligne avec les attentes - Telefonica publie un CA du T1 2024 en hausse de 2% à 10 140 M€ (1% au-dessus du consensus de 10 057 M€), porté par le Brésil (croissance de 10%). L’EBITDA ressort en hausse de 2% à 3 205 M€ (1% au-dessus du css de 3 174 M€) mais l’EBITDAaL simplement en ligne. Le FCF au T1 2024 ressort en négatif de 44 M€ (vs consensus de gain de 111 M€). Les objectifs 2024 sont confirmés. Pour 2024, Telefonica vise une croissance du CA de...
- Jean-François Granjon
Prysmian : Un début d’exercice supérieur aux attentes – Guidances conf...
>Publication des résultats T1 supérieurs aux attentes - Prysmian publie des résultats T1 supérieurs à nos attentes et celles du consensus. Le CA trimestriel ressort à 3.687 M€ (4052.2 M€ estimé, 3709.7 M€ pour le Css) vs 3992 M€ en repli de 7.6% et de -5.6% en organique. Les résultats trimestriels traduisent une légère baisse de l’EBITDA ajusté de 3.5% à 412 M€ (382 M€ estimé, 384.3 M€ pour le Css) vs 427 M€ YoY. La marge d’EBITDA ajustée ressort ainsi à 11.2% (9.4% e...
- Emna Ben Bdira
- Maxime Kogge
Aurubis : Outlook still in good shape despite ongoing TC/RC slump
>Positive indications on H2 thanks to metals prices and recycling - Aurubis’ Q2 2023-24 results (to end-March), reported yesterday, were pretty good and in line with expectations (see our first take published yesterday). But the market reaction was mixed, with the stock shedding up to 3.5% to end the day down 0.9%. And yet Aurubis slightly upgraded its outlook with the CEO Roland Harings indicating in the call that he now expects to stand in the midrange of the 2023...
- Emmanuel Matot
- Martin Marandon-Carlhian
Nexi S.p.A : Bon début d’année par rapport aux guidances annuelles
>Croissance organique du CA et de l’EBITDA au-dessus des attentes au T1 - Nexi vient de publier ses résultats au titre du T1 2024. Ils dépassent les attentes avec un CA en croissance organique de 6.0% à 782 M€ (vs ODDO BHF / consensus = +4.5/+5.3% à 775/776 M€ - rappel 2023 = +7.0%) et un EBITDA en progression proforma de 8.6% à 362 M€ (vs ODDO BHF / consensus = +6.1/+6.5% à 356/355 M€) soit une marge d’EBITDA en hausse comparable de 112 pb à 46.3% (vs ODDO BHF / con...
Sogefi: 1 director
A director at Sogefi sold 100,000 shares at 3.010EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
- Thomas Vranken
argenx FIRST LOOK: 1Q24 results on track, all eyes set on CIDP
This morning argenx reported its 1Q24 update, highlighting $ 398m sales and its pipeline progress. Mgmt is fully focused on expanding its commercial footprint into CIDP (PDUFA: June 21). Meanwhile, AAV was scrapped from the pipeline and systemic sclerosis (SSC) added. We maintain our € 435 TP and Buy rating.
Moody's Ratings assigns definitive ratings to Taurus 2024-1PP auto ABS
Moody's Ratings (Moody's) has assigned the following definitive ratings to notes issued by BNY Trust Company of Australia Limited in its capacity as the trustee of the Taurus 2024-1PP Trust. IMPORTANT NOTICE: MOODY'S RATINGS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS. SUCH USE W...
- Paul Charpentier
Nexi - Solid start to the year
Nexi reported solid numbers in Q1 2024 with 6.0% revenue growth that was 70bp above expectations. As the consensus already factors in a deceleration in organic growth and a contained increase in profitability for FY2024e, we see limited downside to current expectations. Given that the valuation mul
- Oscar Haffen Lamm
MedinCell: Continues to deliver! We are confident on the safety readou...
Yesterday, Teva and MedinCell announced positive phase 3 efficacy results from its phase 3 trial evaluation mdc-TJK (TEV-'749), a LAI olanzapine, as a once-monthly SC LAI in adults with Schizophrenia. The study met its primary endpoint achieving stat. sig. reductions across all three mdc-TJK doses
Catella AB: 2 directors
Two Directors at Catella AB bought/maiden bought 22,000 shares at between 30.430SEK and 30.500SEK. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
South Plains Financial Inc: 2 directors
Two Directors at South Plains Financial Inc sold/bought 80,000 shares at 25.000USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
- Damien Choplain
- Martial Descoutures
Argenx : La montée en puissance des produits se poursuit
>T1 en ligne sur les ventes, en dessous sur l’EBIT - Les ventes T1 progressent de 83% y-o-y et de 6% q-o-q pour atteindre 398 M$ (US 347 M$, Japon 18 M$ et EMEA 31 M$), reflétant le fort besoin médical dans la Myasthénie Gravis, la qualité des produits (i.e. Vyvgart et Vyvgart Hytrulo), ainsi que l’excellente exécution du déploiement commercial. Le produit devrait rester sur cette trajectoire de croissance pour atteindre un peak sales estimé à 11 Md$ (vs css 11 Md$) ...
- Anthony Dick
- Michael Foundoukidis
BMW : Decent in relative terms, but that may not be enough
>Q1 slightly below expectations for Autos, 2024 guidance confirmed - BMW reported yesterday morning a set of Q1 2024 results that came in line with expectations overall, but a shade below on the core Autos division (-6% vs css EBIT), see First Take. Whilst volumes were broadly stable over the quarter, the group, like most of its peers, posted lower earnings (EBIT -25% y-o-y, of which -28% for the Automotive division), penalised by falling prices (new and used vehicl...
Form 8.5 (EPT/RI) - Abrdn European Logistics Income Plc
Form 8.5 (EPT/RI) - Abrdn European Logistics Income Plc FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Investec Bank plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeabrdn European Logistics Income plc(c) Name of the party to the offer with which exempt principal trader is...
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinic...
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, announced that it has initiated its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants – see Neur...
Form 8.5 (EPT/RI) - Alpha Financial Markets Consulting Plc
Form 8.5 (EPT/RI) - Alpha Financial Markets Consulting Plc FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Investec Bank plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeAlpha Financial Markets Consulting plc(c) Name of the party to the offer with which exempt principal tra...
e-therapeutics plc shares now trading on JP Jenkins
JP Jenkins Ltd e-therapeutics plc shares now trading on JP Jenkins 09-May-2024 / 07:30 GMT/BST The issuer is solely responsible for the content of this announcement. 9th May 2024 JPJ: ETX ISIN: GB00B2823H99 e-therapeutics plc ("e-therapeutics" or "ETX" or the "Company") Shares now trading on JP Jenkins London, UK, 9th May 2024 – e-therapeutics plc (AIM: ETX), a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announces its shares (“ETX”) () have been admitted to trade on JP Jenkins share dealing plat...
- Trung Nguyen
Lippo Malls Indonesia - Event Flash - Exchange Offer For 2024 Notes; Q...
Yesterday, Lippo Malls Indonesia Retail Trust (LMIRT) launched an exchange offer for the USD 7.25% 2024 notes maturing on June 19th, with an outstanding amount of USD 138.4 mn. The company has offered to exchange each of the USD 1,000 principal of the notes for USD 432 of USD 7.5% 2026 notes and a USD 600 cash payment. The funding will come from a credit facility of up to IDR 1.5 tn. We recommend that holders of the 2024 notes participate in the offer. Considering that it requires 70% of hol...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.